obesity

Adrenal and pituitary disorders

Adrenal and pituitary disorders

All glands are created equal, but some glands are more equal than the others. Understanding the complications and the development of new treatments for pituitary and adrenal disorders has exploded in the past decades. We have contributed to investigating and systematically analyzing the available evidence. Our favorite condition is the most difficult of them all, Cushing's syndrome. Nonetheless, the international community has also appreciated our research on obesity, the metabolic effect of GH, and the treatments used to manage its excess.

Modeling the contribution of the obesity epidemic to the temporal decline in sperm counts

Objective: Total sperm count (TSC) has been declining worldwide over the last several decades due to unknown etiologies. Our aim was to model the contribution that the obesity epidemic may have on declining TSC.

Materials and methods: Obesity rates were determined since 1973 using the WHO's Global Health Observatory data. A literature review was performed to determine the association between TSC and obesity. Using the measured obesity rates and published TSC since 1973, a model was created to evaluate the association between temporal trends in obesity/temperature and sperm count.

Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity

PURPOSE: In morbid obesity nonalcoholic fatty liver disease (NAFLD) is endemic. Aim of this study is to evaluate the diagnostic accuracy of the most common noninvasive methods for identify NAFLD and fibrosis in a cohort of morbid obese population. METHODS: Ninety morbid obese patients undergoing bariatric surgery (BS) and intraoperative liver biopsy were evaluated preoperatively with Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) and serum biomarkers for steatosis and fibrosis and liver stiffness measurement (LSM) using acoustic radiation force impulse (ARFI) elastography.

The TAP block in obese patients. Pros and cons

The growing number of laparoscopic surgical procedures performed in obese patients has increased the need to explore suitable analgesic techniques for a prone population to postoperative complications. The morbidly obese population may particularly benefit from the opioid-sparing or the opioid-free anesthesia/analgesia, which maximize the use of locoregional techniques. Transversus abdominal plane (TAP) block has been widely used as part of multimodal analgesia for abdominal and gynecological surgeries, but evidence in obese patients is still poor.

Obesity and kidney stone disease. A systematic review

INTRODUCTION: Currently, abdominal obesity has reached an epidemic stage and obesity represents an important challenge for worldwide health authorities. Epidemiologic studies have demonstrated that the stone risk incidence increases with Body Mass Index, through multiple pathways. Metabolic syndrome and diabetes are associated with an increased renal stones disease incidence. The aim of this systematic review was to investigate the prevalence, morbidity, risk factors involved in the association between obesity and urolithiasis.

Metabolic surgery and depression

The incidence of obesity is rising worldwide and so are its comorbidities: type-2 diabetes mellitus (T2DM), dyslipidaemia, hypertension, cardiovascular disease, sleep apnoea, and depression. Bariatric/metabolic surgery has established itself over the past several years as an effective treatment not only for morbid obesity but also for its associated morbidities. The effects of bariatric/metabolic surgery on depression are controversial, with some studies showing improvement and others demonstrating a worsening.

Roles of gut hormones in the regulation of food intake and body weight

The gastrointestinal tract is extremely rich in endocrine cells and secretes a myriad of hormones, including ghrelin, glucagon-like peptide 1(GLP1), gastric inhibitory peptide (GIP), cholecystokinin (CCK), amylin, peptide YY (PYY), oxyntomodulin, and leptin. Mechanical distention of the stomach elicits mechanoreceptors within the gastric wall sensing tension, stretch, and volume, which then send brain signals through vagal and spinal sensory nerves.

Lack of association between obesity and aggressiveness of differentiated thyroid cancer

PURPOSE:
Aim of this study was to evaluate the association between body mass index (BMI) and aggressive features of differentiated thyroid cancer (DTC) in a prospective cohort.
METHODS:
Patients with DTC were prospectively enrolled at a tertiary referral center and grouped according to their BMI. Aggressive clinic-pathological features were analyzed following the American Thyroid Association Initial Risk Stratification System score.
RESULTS:

Complications of intragastric balloons

The American Society for Gastrointestinal Endoscopy (ASGE) and the American Society for Metabolic and Bariatric Surgery (ASMBS) have defined acceptable thresholds of safety and efficacy for primary endoscopic bariatric therapies (EBTs). Specifically, a given EBT should have an incidence of serious adverse events ≤5% and should result in ≥25% excessive weight loss (EWL) at 12 months, and this EWL should be ≥15% higher than in a control group. In recent decades, several intragastric balloons (IGBs) have demonstrated safety and efficacy, with broad adoption internationally. The U.S.

The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway

Mineralocorticoid receptor antagonists (MRAs) are recommended for the treatment of heart failure and hypertension, mainly due to their natriuretic and anti-fibrotic mode of action. Rodent studies have shown that MRAs can prevent adverse metabolic consequences of obesity but an elucidation of underlying molecular mechanisms is missing. Here, we investigated metabolic effects of the novel non-steroidal MRA finerenone (FIN) in a mouse model of high-fat diet (HFD)-induced obesity and the signaling pathways activated by MR antagonism at level of interscapular brown adipose tissue (iBAT).

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma